Literature DB >> 2906760

Sulfasalazine in the rheumatic disease.

R S Pinals1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2906760     DOI： 10.1016/0049-0172(88)90010-8

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN： 0049-0172            Impact factor:   5.532


× No keyword cloud information.
  7 in total

1.  [Not Available].

Authors:  C Grondin
Journal:  Can Fam Physician       Date:  1990-03       Impact factor: 3.275

2.  Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.

Authors:  G C Kaiser; F Yan; D B Polk
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

Review 3.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

4.  Ankylosing spondylitis. Current drug treatment.

Authors:  J T Gran; G Husby
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

5.  Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

Authors:  D Caspi; D Fuchs; M Yaron
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 6.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 7.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.